Isabel Britsch

ORCID

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 6

Top Venues

Oncoimmunology

Cancers

Journal for immunotherapy of cancer

Universitair Medisch Centrum Groningen

Rijksuniversiteit Groningen (MSC)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Universitair Medisch Centrum Groningen Oct 15 2019

Netherlands

PhD student :: Sugery

Education History

Rijksuniversiteit Groningen Aug 15 2017 - Jul 15 2019

Netherlands

MSC

Uppsala University Aug 15 2017 - Jul 15 2019

Sweden

MSC

Eberhard Karls Universität Tübingen Oct 01 2013 - Jul 30 2017

Germany

BSC

Publications

Isabel Britsch, Anne Paulien van Wijngaarden, Xiurong Ke, Mark Alexander Johannes Martinus Hendriks, Douwe Freerk Samplonius, Emily Maria Ploeg, Wijnand Helfrich
Novel Fab-peptide-HLA-I fusion proteins for redirecting pre-existing anti-CMV T cell immunity to selective eliminate carcinoma cells. Oncoimmunology 12 (1) (2023)
Isabel Britsch, Anne Paulien van Wijngaarden, Wijnand Helfrich
Applications of Anti-Cytomegalovirus T Cells for Cancer (Immuno)Therapy. Cancers 15 (15) (2023)
Emily Maria Ploeg, Douwe Freerk Samplonius, Xiao Xiong, Xiurong Ke, Mark Alexander Johannes Martinus Hendriks, Isabel Britsch, Anne Paulien van Wijngaarden, Hao Zhang, Wijnand Helfrich
Bispecific antibody CD73xEGFR more selectively inhibits the CD73/adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFR. Journal for immunotherapy of cancer 11 (9) (2023)
Isabel Britsch, Anne Paulien van Wijngaarden, Xiurong Ke, Mark Alexander Johannes Martinus Hendriks, Douwe Freerk Samplonius, Emily Maria Ploeg, Wijnand Helfrich
Novel Fab-peptide-HLA-I fusion proteins for redirecting pre-existing anti-CMV T cell immunity to selective eliminate carcinoma cells. Oncoimmunology 12 (1) (2023)
Mark Alexander Johannes Martinus Hendriks, Isabel Britsch, Xiurong Ke, Anne Paulien van Wijngaarden, Douwe Freerk Samplonius, Emily Maria Ploeg, Wijnand Helfrich
Cancer cells under immune attack acquire CD47-mediated adaptive immune resistance independent of the myeloid CD47-SIRPα axis. Oncoimmunology 10 (1) (2021)
Mark Alexander Johannes Martinus Hendriks, Emily Maria Ploeg, Iris Koopmans, Isabel Britsch, Xiurong Ke, Douwe Freerk Samplonius, Wijnand Helfrich
Bispecific antibody approach for EGFR-directed blockade of the CD47-SIRPα "don't eat me" immune checkpoint promotes neutrophil-mediated trogoptosis and enhances antigen cross-presentation. Oncoimmunology 9 (1) (2020)

Isabel Britsch.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Isabel Britsch